Skip to main content

Response to “Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study”

A Letter to this article was published on 11 February 2020

A Letter to this article was published on 11 February 2020

The Original Article was published on 27 July 2019

In the last issue of Arthritis Research & Therapy, Henrotin et al. [1] report the outcomes of a double-blind multicenter randomized placebo controlled, three-arm study assessing the effect of two doses of bio-optimised Curcuma longa (BCL) on the symptoms of knee osteoarthritis (OA). They conclude in the “key messages” that BCL is an efficient and safe treatment to relieve pain in knee OA patients.

It is our perception that this conclusion is likely to be misleading, as it is not supported by the content of the article.

To begin with, this trial, which is an exploration study initiated on May 2014, has been registered retrospectively on September 21, 2016, a major abnormality which should have been but is not explained in the paper. It is not a common practice to register a clinical trial more than 2 years after the study start date, as it is well known that this practice has been implemented to be a safeguard of the overall conduct of the study.

Importantly, the authors selected two co-primary endpoints, i.e. Patient Global Assessment of Disease Activity (PGADA) and serum sColl2-1, to be assessed as the changes observed from baseline to day 90 of treatment. The choice of the co-primary endpoints selected by the authors is unusual, being different from those recommended by regulatory agencies or by most respected scientific organisations, i.e. pain and function.

In the intention-to-treat (ITT) analysis, the changes observed in both co-primary endpoints, in each of the BCL treatment groups, failed to reach the level of statistical significance compared to the changes observed in the placebo group. Therefore, in terms of efficacy, this study should be considered as a failure. Moreover, it is scientifically unsound to conduct post hoc tests or to re-analyse the primary endpoints in secondary populations (full analysis set or per-protocol population) when the primary endpoints are not met in the ITT population.

According to the method, the study was registered as a 6-month study and was conducted as such, as shown in the flow chart of the study (Fig. 1). However, the authors do not give any information on the outcomes observed between the primary analysis (month 3) and the end of study (month 6), except for a rather high, hence suspicious rate of withdrawals between month 3 and month 6, raising safety concerns about the BCL treatment.

At month 3, the authors report significantly more adverse events related to the product in the BCL high dose than in the BCL low dose and placebo, with abdominal discomfort and diarrhea being the most frequently reported adverse events. Knowing that the plateau curcumin levels were somewhat comparable in the high- and low-dose BCL groups, such results generate major concerns about the gastro-intestinal safety of the product.

Moreover, the authors originally planned a dropout rate of 15%, and they faced significantly higher dropout rates, i.e. 23.4% in the placebo group, 34.7% in the BCL low-dose group and 38.9% in the high BCL dose group. The reasons for dropouts are not properly explained in Fig. 1, e.g. n = 21 discontinued in the ITT BCL high-dose group but only 18 reasons for dropout provided in Fig. 1.

In summary, we have several major concerns about the design and concept of this study and about the support of the conclusions by the scientific evidence provided.

An appropriate conclusion would be that this study does not support that the actual Curcuma longa formulation used in this study is an effective treatment for the management of symptoms in knee osteoarthritis. Moreover, serious concerns are raised regarding the innocuity of the compound.

Availability of data and materials



  1. Henrotin Y, Malaise M, Wittoek R, et al. Arthritis Res Ther. 2019;21:179.

    Article  CAS  Google Scholar 

Download references




No funding sources to declare.

Author information

Authors and Affiliations



JPP and JPR contributed to the design and drafting of this letter. Both authors read and approved the final manuscript.

Authors’ information

Jean-Pierre Pelletier, MD

Professor of Medicine, University of Montreal

Head, Chair in Osteoarthritis of the University of Montreal

Director, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM)

Accredited member, Department of Pharmacology & Physiology, University of Montreal

Montreal, Quebec, Canada

Jean-Pierre Raynauld, MD, FRCPC

Clinical Assistant Professor, University of Montreal

Member, Rheumatology Division, Montreal University Hospital Centre (CHUM)

Director of Clinical Research Trials in Osteoarthritis, Montreal Rheumatology Insititute

Montreal, Quebec, Canada

Corresponding author

Correspondence to Jean-Pierre Pelletier.

Ethics declarations

Ethics approval and consent to participate


Consent for publication


Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pelletier, JP., Raynauld, JP. Response to “Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study”. Arthritis Res Ther 22, 22 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: